Comment from Mobius Therapeutics, LLC (Arnall Golden Gregory LLP)
AnonymousOpposeBusiness
Summary: Mobius Therapeutics, represented by legal counsel Arnall Golden Gregory LLP, argues that mitomycin should not be included on the Bulk Substances List. They contend that there is no unmet clinical need for compounding mitomycin, as FDA-approved products are readily available and provide safer, more stable formulations.
Attached is Mobius Therapeutics' comment on the nomination of mitomycin,
Submitted by Deborah Livornese, Esquire
Arnall Golden Gregory LLP
1775 Pennsylvania Avenue NW, Suite 1000
Washington, DC 20006
(202) 677-4922
deborah.livornese@agg.com